Clarivate increases its intellectual property footprint

Clarivate acquired Rowan TELS to enhance support for patent ractitioners and launched the IP Collaboration Hub


Clarivate announced the acquisition of Rowan TELS Corporation, through a subsidiary, on 22 July 2024. Rowan TELS Corp. is the provider of Rowan Patents, an integrated patent drafting and prosecution solution specially designed for patent practitioners to establish and protect patents more effectively.

This acquisition will enable Clarivate to extend its workflow automation solutions beyond its existing IP management and intelligence capabilities, delivering new comprehensive and integrated solutions to support patent preparation, filing and prosecution. It also positions Clarivate to provide patent practitioners in this emerging market with automation and responsible AI-enabled solutions that facilitate the efficient delivery of high-quality patent applications.

Gordon Samson, President, Intellectual Property, Clarivate, said: “Rowan Patents will help Clarivate bring together AI and intelligent automation tools to support critical attorney tasks.”

Clarivate has been expanding software support across the IP lifecycle and making ongoing enhancements to its leading patent maintenance, IP management software (IPMS), and IP intelligence capabilities. As part of this strategy, Clarivate announced the launch of IP Collaboration Hub on 24 June. The new solution integrates with Clarivate IP management systems (IPMS) to provide a central hub for collaborating with local agents worldwide.

It provides a portal for instructors and local agents to collaborate and exchange information, while automatically docketing everything in the IPMS. This portal addresses a critical issue in the IP industry—over-reliance on email for communication—which introduces risk into the process. The Hub automates and standardizes communication management between law firms, corporations and their local agents.

Clarivate also introduced a new OFF-X platform, which delivers crucial drug and target safety intelligence to proactively identify risks. Fully integrated with Cortellis Drug Discovery Intelligence, OFF-X provides a comprehensive, one-stop resource for safety information, streamlining processes and enhancing efficiency which ultimately delivers a competitve edge. Learn more about OFF-X here.